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Abstract
Background: Although sentinel lymph node (SLN) biopsy is a standard of care for the evaluation
of the axillary lymph nodes during breast cancer surgery, a substantial degree of variation exists
among individual surgeons as to what represents an adequate assessment. The aim of the current
study was to assess when metastatic disease was first identified within consecutively harvested SLN
candidates for invasive breast cancers demonstrating a positive SLN.
Methods: We retrospectively analyzed a series of 400 breast cancers from a recently published
prospective randomized clinical trial. A combined radiocolloid and blue dye technique was used.
All potential SLN candidates, containing counts of at least 10% of the hottest SLN and/or containing
blue dye, were harvested and were consecutively numbered in the order of the decreasing level of
counts (with the hottest SLN representing SLN #1).
Results: Among 371 invasive breast cancers, a SLN was identified within 353 cases (95%). Mean
number of SLNs identified was 2.5 (range, 1 to 9), with a single SLN identified in 104 (29%) cases,
two identified in 110 (31%), three identified in 73 (21%), four identified in 35 (10%), five identified
in 16 (5%), and six or more identified in 15 (4%). A positive SLN was found in 104 (29%) cases. SLN
#1 was the first positive SLN in 86 (83%). SLN #2 was the first positive SLN in 15 (14%). SLN #3,
SLN #4, and SLN #5 were the first positive SLN in one case (1%) each. A positive SLN was found
in 18% (19/104) of cases when a single SLN was identified, as compared to in 34% (85/249) when
two or more SLNs were identified (P = 0.003).
Conclusion: The accurate and optimal assessment of the axilla during breast cancer surgery
requires persistence and diligence for attempting to identify all potential SLN candidates in order
to avoid failing to recognize a positive SLN. The scenario in which only a single negative SLN
candidate is intraoperatively identified is one that should raise some concern to the operating
surgeon.
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Background
The application of sentinel lymph node (SLN) mapping
and biopsy to the surgical staging of the axilla during
breast cancer surgery has become a universally accepted
standard of practice [1]. Despite widespread use of this
technology, very little emphasis appears to be placed on
defining the adequacy of intraoperative assessment of the
axilla during breast cancer surgery. Defining the concept
of an adequate intraoperative assessment of the axilla
should be based upon any given principle that minimizes
the risk of potentially failing to recognize a positive SLN
and thereby assures accurate axillary staging during breast
cancer surgery. The major determinant in this intraopera-
tive assessment process clearly relates to be the number of
SLNs harvested. In this regard, we have attempted to
address this concept by retrospectively analyzing a series
of 400 breast cancers from a recently published prospec-
tive randomized clinical trial [2] and determining when
metastatic disease was first identified within consecutively
harvested SLNs from those invasive breast cancers demon-
strating a positive SLN.
Methods
We retrospectively analyzed a series of 400 breast cancers
(including 392 patients with unilateral breast cancer and
4 patients with synchronous bilateral breast cancers) from
a recently published prospective randomized clinical trial
that was conducted to evaluate the efficacy of the intrader-
mal, intraparenchymal, and subareolar injection routes
for the administration of radiocolloid [2]. A detailed
description of patient eligibility, study design, and study
execution for this recently completed prospective rand-
omized clinical trial has been previously reported [2]. This
previously reported series of 400 breast cancers included
371 cases of invasive breast cancer and 29 cases of ductal
carcinoma in situ (DCIS). For the purposes of this current
report, only the invasive breast cancers were included for
analyses.
On the day of surgery, all patients were injected with
approximately 400 µCi of 99 mTc-sulfur colloid (filtered to
0.20 or 0.22 microns/micrometers) by either the intrader-
mal, intraparenchymal, or subareolar injection route.
Intraoperatively, patients were injected intraparenchy-
mally with approximately 5 mL of blue dye. This was gen-
erally 1% isosulfan blue dye. However, 1% methylene
blue dye was used during periods of time when 1% isosul-
fan blue dye was not commercially available. One patient
inadvertently did not receive an intraparenchyal blue dye
injection. All SLNs were identified by using a hand-held
gamma probe detection unit to detect radiocolloid
("hot") uptake and using visual inspection to detect blue
dye ("blue") uptake. One of two hand-held gamma probe
detection units was available for use by the operating sur-
geon, and consisted of either the Navigator GPS unit
(Tyco Healthcare, Mansfield, Massachusetts) or the Neo-
probe neo2000 unit (Neoprobe Corporation, Dublin,
Ohio). As previously reported [2], a SLN was defined as
any lymph node that was either "hot" and "blue", "hot"
only, or "blue" only. A "hot" SLN was defined as any
lymph node which contained a level of radioactivity that
was 10% or greater of the total level of radioactivity found
in the "hottest" SLN. A "blue" SLN was defined as any
lymph node which visibly stained blue, had a contiguous
blue-stained afferent lymphatic channel, or both. All
potential SLN candidates, containing radiocolloid counts
of at least 10% of the hottest SLN and/or containing blue
dye, were harvested and were consecutively numbered in
the order of the decreasing level of radiocolloid counts. In
this regard, the hottest SLN was defined as SLN #1, regard-
less of the arbitrary order in which it was harvested along
with the other SLNs.
Frozen section analysis with hematoxylin-eosin staining
was generally performed on all submitted SLN candidates
at the time of surgery. An axillary lymph node dissection
was performed at the time of the SLN biopsy if any SLNs
were found to contain malignant cells on frozen section
analysis. Subsequently, all submitted SLNs were serially
sectioned and stained with hematoxylin-eosin and immu-
nohistochemical staining for cytokeratins (AE1:AE3) was
performed.
For categorical variable univariate comparisons, either
Pearson chi-square test or Fisher exact test was utilized.
Continuous variables were expressed as means (± stand-
ard deviation) and/or median (range). For continuous
variable univariate comparisons, one-way analysis of var-
iance (ANOVA) was utilized. All reported univariate P-val-
ues were two-sided. All univariate P-values determined to
be 0.05 or less were determined to be significant. Multi-
variate logistic regression analysis was then performed on
all variables with a univariate P-value of 0.100 or less for
the determination of possible independent predictors.
The software program SPSS 14.0 for Windows (SPSS, Inc.,
Chicago, Illinois) was used for all statistical analyses.
Results
Among 371 invasive breast cancers, a SLN was identified
within 353 cases (95%). This included a "hot" SLN in
95% (352/371) of cases and a "blue" SLN in 68% (252/
370) of cases. Of the 352 patients injected with both 99
mTc-sulfur colloid and IP blue dye, the SLNs were both
"hot" and "blue" in 71% (251/352), "hot" only in 28%
(100/352), and "blue" only in 0.3% (1/352). Axillary con-
cordance (defined as the proportion of cases in which
both 99 mTc-sulfur colloid and IP blue dye localized to the
same axilla, and at least one SLN was both "hot" and
"blue") was seen in 97% (245/252) of cases.World Journal of Surgical Oncology 2007, 5:18 http://www.wjso.com/content/5/1/18
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The mean number of SLNs identified was 2.5 (range, 1 to
9), with a single SLN identified in 29% (104/353) of
cases, two SLNs identified in 31% (110/353), three SLNs
identified in 21% (73/353), four SLNs identified in 10%
(35/353), five SLNs identified in 5% (16/353), and six or
more SLNs identified in 4% (15/353).
A positive SLN was found in 29% (104/353) of cases. A
positive SLN was found in 18% (19/104) of cases when a
single SLN was identified, as compared to in 34% (85/
249) of cases when two or more SLNs were identified (P =
0.003). Patient demographics, tumor characteristics, and
intraoperative variables were compared for those invasive
breast cancers in which one SLN was identified versus two
or more SLNs were identified (Table 1). Univariate analy-
sis revealed that greater body weight (P = 0.041), increas-
ing breast size (P = 0.053), and more differentiated
tumors (P = 0.032) were associated with a higher likeli-
hood of identifying only a single SLN. A similar trend was
seen for greater body mass index (BMI), but this did not
reach statistical significance (P = 0.101) on univariate
analysis. However, multivariate logistic regression analy-
sis revealed no independent predictors of the likelihood
of identifying only a single SLN.
SLN #1 was the first positive SLN in 83% (86/104) of
cases. SLN #2 was the first positive SLN in 14% (15/104),
with SLN #2 containing a mean of 45% (range, 5% to
86%) of the total counts of the hottest SLN. SLN #3, SLN
#4, and SLN #5 were the first positive SLN in one case
(1%) each, with SLN #3, SLN #4, and SLN #5 containing
17%, 14%, and 15% of the total counts of the hottest SLN,
respectively. For all SLN-positive invasive breast cancers,
patient demographics, tumor characteristics, and intraop-
erative variables were compared for those cases in which
SLN #1 was the first positive SLN versus those cases in
which SLN #1 was not the first positive SLN (Table 2).
Univariate analysis revealed that older patient age (P =
0.042), smaller pathologic T-stage (T1 versus T2/T3) (P =
0.056), and lobular and/or mixed ductal-lobular histopa-
thology (P = 0.032) were associated with a higher likeli-
hood of SLN #1 not being the first positive SLN in SLN-
positive invasive breast cancers. A similar trend was seen
for the absence of lymphovascular invasion, but this did
not reach statistical significance (P = 0.101) on univariate
analysis. However, multivariate logistic regression analy-
sis revealed no independent predictors of the likelihood
of SLN #1 not being the first positive SLN in SLN-positive
invasive breast cancers.
Table 3 shows the classification of metastatic disease
within the first positive SLN for cases of invasive breast
cancers in which SLN #1 was the first positive SLN versus
cases in which SLN #1 was not the first positive SLN. The
distribution of macrometastatic disease (> 2 mm) and
micrometastatic disease (≤ 2 mm, but > 0.2 mm) were not
statistically significantly different in the group in which
SLN #1 was the first positive SLN versus the group in
which SLN #1 was not the first positive SLN (P = 0.605 for
macrometastatic disease and P = 0.759 for micrometa-
static disease, respectively). However, submicrometastatic
disease (≤ 0.2 mm) showed a statistically nonsignificant
(P = 0.095) trend toward being more frequently seen in
the group in which SLN #1 was not the first positive SLN.
In the same regard, Table 4 shows the specific estimated
size (in centimeters) of metastatic disease within the first
positive SLN for cases of invasive breast cancer based on
which of the consecutively numbered SLNs was first
involved. Although one-way ANOVA of the data in Table
4 appears to show a similar trend toward decreasing size
of metastatic disease with increasing consecutively num-
bered first positive SLNs, analogous to that found in Table
3, this trend in Table 4 was also not statistically significant
(P = 0.104). Therefore, the data in Tables 3 and 4 do not
clearly demonstrate a significant relationship between the
volume of metastatic disease found within a given SLN
and the likelihood that the hottest versus non-hottest SLN
would be the first SLN to contain metastatic disease.
Discussion
Despite the vast body of existing literature on SLN tech-
nology for breast cancer (with over 2700 publications to
date), it is surprising how few papers have specifically
addressed the concept of how the number of SLN candi-
dates harvested during breast cancer surgery influences the
adequacy of intraoperative assessment of the axilla [3-15].
To their credit, two well-respected groups (the University
of Louisville Breast Cancer SLN Multiinstitutional Study
group [3,4,12] and the Memorial Sloan-Kettering Cancer
Center group[5,6]) have previously attempted to most
clearly bring this concept to our attention. However,
despite their attempts to bring this concept to the fore-
front of the surgical literature, there is an apparent ongo-
ing lack of awareness among the general surgical
community as to its importance. This has clearly resulted
in a paucity of formalized published guidelines to help
individual surgeons optimize the accurate assessment of
the axilla during breast cancer surgery. In the current
study, we have attempted to again re-emphasize this con-
cept of what represents an optimal assessment of the axilla
by retrospectively analyzing our recently published pro-
spective randomized SLN clinical trial [2].
In the current study, while 83% of cases had the positive
SLN identified as the hottest SLN, 17% of cases had the
positive SLN identified as the second, third, fourth, or
fifth hottest SLN. Similarly, the SLN was positive in a sig-
nificantly greater frequency of cases when two or more
SLNs were found as compared to when a single SLN was
found (34% versus 18%, P = 0.003). Taken together, theseWorld Journal of Surgical Oncology 2007, 5:18 http://www.wjso.com/content/5/1/18
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Table 1: Patient demographics, tumor characteristics, and intraoperative variables of invasive breast cancers (n = 353) in which a one 
SLN was identified versus two or more SLNs were identified.
One SLN identified (n = 104) Two or more SLNs identified (n = 249) P-value
Age (mean ± SD, years) 56 ± 11 56 ± 12 0.870
Height (mean ± SD, inches) 64 ± 3 64 ± 2 0.386
Weight (mean ± SD, pounds) 174 ± 45 165 ± 35 0.041
BMI (mean ± SD, kg/m2) 29.5 ± 6.9 28.3 ± 6.0 0.101
Breast size 0.053
Small 6 (6%) 25 (10%)
Medium 31 (30%) 101 (41%)
Large 41 (39%) 83 (33%)
Not available 26 (25%) 40 (16%)
Palpable tumor 53 (51%) 120 (48%) 0.635
Tumor location 0.259
UOQ 51 (49%) 142 (57%)
LOQ 21 (20%) 33(13%)
UIQ 20 (19%) 38 (15%)
LIQ 9 (9%) 21 (8%)
Central 3 (3%) 15 (6%)
Type of diagnostic breast biopsy 0.301
Core 79 (76%) 191 (77%)
Excisional 24 (23%) 58 (23%)
Fine needle aspiration 1 (1%) 0 (0%)
Pathologic T-stage 0.617
T1 68 (65%) 176 (71%)
T2 34 (33%) 69(28%)
T3 2 (2%) 4 (2%)
Histopathology 0.958
Ductal 90 (87%) 216 (87%)
Lobular 3 (3%) 18 (7%)
Mixed Ductal-Lobular 3 (3%) 9 (4%)
Other 8 (8%) 6 (2%)
Histologic grade 0.032
Well-differentiated 11 (11%) 56 (23%)
Moderately-differentiated 47 (45%) 101 (41%)
Poorly-differentiated 46 (44%) 92 (37%)
Estrogen receptor positive 77 (74%) 198 (80%) 0.258
Progesterone receptor positive 63 (61%) 165 (66%) 0.308
HER-2/neu positive 27 (26%) 46 (19%) 0.136
Lymphovascular invasion 24 (23%) 48 (19%) 0.419
Route of injection of 99 mTc-sulfur colloid 0.428
Intradermal 33 (32%) 92 (37%)
Intraparenchymal 38 (37%) 74 (30%)
Subareolar 33 (32%) 83 (33%)
Surgery performed at time of SLN biopsy 0.184
Lumpectomy 80 (77%) 169 (68%)
Mastectomy 21 (20%) 74 (30%)
SLN biopsy alone 3 (3%) 6 (2%)
Time from 99 mTc-sulfur colloid injection to SLN biopsy (mean ± 
SD, minutes)
290 ± 78 287 ± 66 0.682
BMI, body mass index; UOQ, upper outer quadrant; LOQ, lower outer quadrant; UIQ, upper inner quadrant; LIQ, lower inner quadrant; SLN, 
sentinel lymph node.World Journal of Surgical Oncology 2007, 5:18 http://www.wjso.com/content/5/1/18
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Table 2: Patient demographics, tumor characteristics, and intraoperative variables of sentinel lymph node positive invasive breast 
cancers (n = 104) in which SLN#1 was and was not the first positive SLN.
SLN#1 was first positive SLN (n = 86) SLN#1 was not first positive SLN (n = 18) P-value
Age (mean ± SD, years) 53 ± 11 59 ± 11 0.042
Height (mean ± SD, inches) 64 ± 2 64 ± 2 0.804
Weight (mean ± SD, pounds) 164 ± 31 165 ± 36 0.883
BMI (mean ± SD, kg/m2) 28.2 ± 5.7 28.2 ± 6.1 0.984
Breast size 0.991
Small 9 (11%) 2 (11%)
Medium 35 (41%) 7 (39%)
Large 30 (35%) 6 (33%)
Not available 12 (14%) 3 (17%)
Palpable tumor 54 (63%) 12 (67%) 0.756
Tumor location 0.352
UOQ 45 (52%) 11 (61%)
LOQ 19 (22%) 2 (11%)
UIQ 9 (10%) 4 (22%)
LIQ 5 (6%) 1 (6%)
Central 8 (9%) 0 (0%)
Type of diagnostic breast biopsy 0.380
Core 66 (77%) 12 (67%)
Excisional 20 (23%) 6 (33%)
Pathologic T-stage 0.056
T1 41 (48%) 14 (78%)
T2 40 (47%) 3 (17%)
T3 5 (6%) 1 (6%)
Histopathology 0.032
Ductal 79 (92%) 13 (72%)
Lobular 4 (5%) 2 (11%)
Mixed Ductal-Lobular 2 (2%) 3 (17%)
Other 1 (1%) 0 (0%)
Histologic grade 0.584
Well-differentiated 12 (14%) 4 (22%)
Moderately-differentiated 31 (36%) 7 (39%)
Poorly-differentiated 43 (50%) 7 (39%)
Estrogen receptor positive 67 (78%) 15 (83%) 0.758
Progesterone receptor positive 55 (64%) 12 (67%) 0.827
HER-2/neu positive 23 (27%) 3 (17%) 0.551
Lymphovascular invasion 37 (43%) 4 (22%) 0.101
Route of injection of 99 mTc-sulfur colloid 0.450
Intradermal 34 (40%) 10 (56%)
Intraparenchymal 24 (28%) 4 (22%)
Subareolar 28 (33%) 4 (22%)
Surgery performed at time of SLN biopsy 0.789
Lumpectomy 49 (57%) 10 (56%)
Mastectomy 35 (41%) 8 (44%)
SLN biopsy alone 2 (2%) 0 (0%)
Time from 99 mTc-sulfur colloid injection to SLN 
biopsy (mean ± SD, minutes)
278 ± 57 283 ± 56 0.705
BMI, body mass index; UOQ, upper outer quadrant; LOQ, lower outer quadrant; UIQ, upper inner quadrant; LIQ, lower inner quadrant; SLN, 
sentinel lymph node.World Journal of Surgical Oncology 2007, 5:18 http://www.wjso.com/content/5/1/18
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results should raise significant concern with any patient
scenario in which only a single negative SLN candidate is
identified intraoperatively.
This general concern with regards to a single SLN candi-
date has previously been raised by the University of Lou-
isville Breast Cancer SLN Multiinstitutional Study group
[3,4,12] and the Memorial Sloan-Kettering Cancer Center
group [5,6]. The most compelling aspect of this concern
relates specifically to the results reported by the University
of Louisville Breast Cancer SLN Multiinstitutional Study
group [3,4,12] for patients who underwent SLN biopsy
and a concomitant confirmatory axillary lymph node dis-
section. In 2001, Wong et al [4] showed a false negative
rate of 14.3% in patients who had one SLN harvested as
compared to 4.3% in patients who had two or more SLNs
harvested (P = 0.0004). Identically, in 2005, Martin et al
[12] reproduced those same results, showing a false nega-
tive rate of 13.7% in patients who had one SLN harvested
as compared to 5.4% in patients who had two or more
SLNs harvested (P < 0.0001). These two studies [4,12], as
well as others [3,5,6,9,13,14], clearly emphasize the
importance of removal of all lymph nodes containing
radioisotope counts, regardless of relative magnitude of
those radioisotope counts in comparison to the hottest
SLN, in order to achieve maximum accuracy for the SLN
biopsy procedure. In contrast, several other previous stud-
ies have not as strongly endorsed this contention
[7,8,10,11,15], with some authors suggesting a focused
histopathologic examination of the first two SLNs on fro-
zen section analysis [7] or the first three SLNs on perma-
nent analysis [11], and with other authors suggesting the
placement of a limit on the "optimal" number of SLNs to
harvest [8,10,15]. Nevertheless, it appears intrinsic and
implied within all the above cited studies [3-15] that the
identification of a single negative SLN impacts negatively
on the accurate assessment of the axilla during breast can-
cer surgery.
While those previous studies [3-6,9,12-14] supporting the
importance of harvesting all radioisotope-containing
lymph nodes have emphasized this concept from the
"more is better" standpoint, conversely they have not
emphasized this concept from the "less is worse" stand-
point. Although potentially redundant, we propose that
one should also emphasize the "less is worse" point of
view since there are as yet no formal criteria for defining
an adequate evaluation of the axilla during breast cancer
surgery. In this regard, this has perpetuated a sense of lim-
ited awareness among the general surgery community.
This limitation in awareness is clearly reflected within the
substantial degree of variation that exists among individ-
ual surgeons with regards to their SLN biopsy methodol-
ogy [16]. Most specifically, we are referring to those
surgeons who routinely identify only a single SLN candi-
date in the vast majority of their breast cancer cases. From
the above body of evidence, those particular patients in
which only a single negative SLN is intraoperatively
obtained are theoretically at greater risk for inadequate
assessment for the axilla, and if harboring unrecognized
metastatic disease are ultimately at risk for not receiving
what would be the most appropriate adjuvant therapy for
their actual, but unrecognized, disease stage. So, it is that
particular practice of routinely only harvesting a single
SLN candidate that raises our intraoperative trepidation.
In this particular situation, we strongly advise persistence
Table 3: Classification of metastatic disease within first positive SLN based on whether SLN#1 was and was not the first positive SLN 
for cases of invasive breast cancer (n = 104).
SLN#1 was first positive SLN (n = 86) SLN#1 was not first positive SLN (n = 18) P-value
Macrometastatic (> 2 mm) 58 (67%) 11 (61%) 0.605
Micrometastatic (≤ 2 mm, but > 0.2 mm) 21 (24%) 3 (17%) 0.759
Submicrometastatic (≤ 0.2 mm) 7 (8%) 4 (22%) 0.095
SLN, sentinel lymph node.
Table 4: Estimated size (in centimeters) of metastatic disease within the first positive SLN for cases of invasive breast cancer (n = 104) 
based on which consecutively numbered SLN was first involved.
First SLN containing metastatic disease Mean size ± SD Median size (range)
SLN #1 (n = 86) 0.721 ± 0.691 0.500 (range, 0.005–3.000)
SLN #2 (n = 15) 0.471 ± 0.440 0.400 (range, 0.020–1.500)
SLN #3 (n = 1) 0.700 0.700
SLN #4 (n = 1) 0.200 0.200
SLN #5 (n = 1) 0.017 0.017
SLN #2, #3, #4, #5 (n = 18) 0.443 ± 0.442 0.400 (range, 0.017–1.500)
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and diligence with the gamma probe for attempting to
identify any additional radioisotope-containing SLN can-
didates in order to potentially avoid failing to recognize a
positive SLN and to assure that the axilla is accurately
staged. Additionally, as previously emphasized by others,
this recommendation for a meticulous intraoperative
search should also include a thorough examination of the
axilla for any blue dye-containing lymph nodes and any
clinically suspicious palpable lymph nodes [3,6,17].
Conclusion
The accurate and optimal assessment of the axilla during
breast cancer surgery requires persistence and diligence for
attempting to identify all potential SLN candidates in
order to avoid failing to recognize a positive SLN. The sce-
nario in which only a single negative SLN candidate is
intraoperatively identified is one that should raise some
concern to the operating surgeon.
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